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Introduction: Antibiotics are recommended as the main therapy for 
preterm premature rupture of membranes (PPROM). But the research 
on antibiotics other than the recommended macrolides regimens is 
still lacking. This research aims to evaluate whether there are effects 
differences of cefotaxime and ceftriaxone given on pregnancy with 
PPROM by comparing the duration of the latency period and the 
infants outcomes. 
Material and Methods: Data was taken through medical records 
retrospectively at Dr. Soetomo Surabaya General Hospital, Indonesia, 
during the period of January-December 2017. The inclusion criteria 
were a history of PPROM in pregnancy <37 weeks, given cefotaxime 
or ceftriaxone therapy, and have labor data. The analysis was perfor-
med by the Mann-Whitney comparison test for the latency period and 
Fisher's exact test for infant outcomes. 
Results: There were 52 samples obtained. The antibiotics used were 
cefotaxime 3 grams once and ceftriaxone 2 grams once. The results 
of the analysis showed that there were no significant differences bet-
ween the types of antibiotics with the length of the latency period, 
with a value of p = 0.601 (p>0.05), where cefotaxime had a median of 
52,67 hours and ceftriaxone was 34,17 hours. Cefotaxime was found 
to be more able to extend the latency period for >48 hours with a 
percentage of 57.8%, whereas in ceftriaxone only 42.9%. There are 
no significant differences in infant outcomes; infant birth weight and 
Apgar score among the two therapies used. 
Conclusion: Cefotaxime was more preferably to be used in the Dr. 
Soetomo Surabaya General Hospital. Although there are no diffe-
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Introduction
Premature rupture of membranes (PROM) is the 
rupture of the membranes before the onset of la-
bor. In many cases, this happens in term pregnancy, 
but when the rupture of membranes occurs befo-
re 37 weeks gestation, this is known as a preterm 
PROM (PPROM) [1, 2]. PPROM complicates about 
3 percent of pregnancies and leads to one-third of 
preterm births. This increases the risk of prematuri-
ty and leads to some other perinatal and neonatal 
complications, including 1 to 2 percent risk of fetal 
death [1].
The incidence of PPROM is not only a problem 
when it causes preterm labor. Women with pro-
longed PPROM are at higher risk for developing 
chorioamnionitis, which can be obtained from an 
increase in bacterial colonization before membrane 
rupture (causing PPROM) or after membrane ruptu-
re (PPROM complications) [3, 4]. The risk of infection 
increases with the decreasing gestational age when 
membrane rupture and the increasing duration of 
the ruptured membrane [3].
The use of antibiotics in women with PPROM 
has been shown to increase the latency period, 
which is defined as the period between ruptured 
membranes and onset of labor [5-8]. There is high-
quality evidence that antibiotics for PPROM can re-
duce the risk of complications due to prematurity 
and the risk of maternal and neonatal infection [7, 
9]. This means that antibiotics can be used at the 
same time to prevent the occurrence of infections 
and help maintain pregnancy in the PPROM to the 
maximum possible time or prevent preterm labor. 
Erythromycin is the first line choice antibiotic used 
for PPROM worldwide, but the recommendation 
was made conditional and there is no consensus 
regarding the best choice to this day. Cephalosporin 
group is another non-famous therapeutic option. 
Some study has already suggested that amoxicillin, 
3rd generation cephalosporins, and erythromycin 
in the association erythromycin-amoxicillin can be 
used and have been shown to improve neonatal 
outcome [10, 11]. But the research on cephalosporin 
and its regimen as a PPROM therapy is still lacking. 
Therefore, this study aims to evaluate whether 
there are effects differences between the new alter-
native cephalosporin antibiotics used in Dr. Soetomo 
Surabaya General Hospital for PPROM; cefotaxime 
and ceftriaxone by comparing the duration of the 
latency period and the infant outcomes.
Methods
 
Study Design and Ethics
This analytic study with a cross-sectional design 
took place from September 2018 - June 2019. 
This research was reviewed by the Health Research 
Ethics Committee of Dr. Soetomo Surabaya General 
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rences in infant outcomes between the two antibiotics, cefotaxime 
appears to be more able to extend the latency period for more than 
48 hours which gives better prospects for fetal lung maturation. Both 
cefotaxime and ceftriaxone have succeeded in preventing infections 
in women with PPROM. 
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Hospital and has been declared "Eligible of Ethics" 
with certificate number 0648/KEPK/Ix/2018 on 
September 21st, 2018. Maternal informed consent 
was obtained through the help of ethics committee. 
We used secondary data in the form of medical 
records taken from the Central Medical Record and 
VK IRD in Dr. Soetomo Surabaya General Hospital. 
The population of this study was all pregnant wo-
men diagnosed with preterm premature rupture of 
membrane (PPROM) in Dr. Soetomo Surabaya Ge-
neral Hospital for January-December 2017 period. 
The diagnosis criteria for PPROM is the rupture of 
membranes without the begin of initial labor signs 
after 1 hour later. We used the 2017 data because 
that is the latest medical records which are com-
plete for a year.
Statistical Analysis 
Samples were obtained using a total sampling te-
chnique so that all parts of the population that met 
the inclusion criteria were taken. The inclusion cri-
teria for this study sample are history of PPROM in 
pregnancies <37 weeks, given cefotaxime or cef-
triaxone therapy, having delivery data, and medical 
records in good and complete condition. Whereas 
the exclusion criteria are patients who did not de-
liver at the Dr. Soetomo Surabaya General Hospital 
and medical records that are damaged and difficult 
to read. The independent variable in this study is the 
antibiotic used in pregnant women with PPROM in 
Dr. Soetomo Surabaya General Hospital. While the 
dependent variable is the length of the latent period 
and the outcome in infants. The time of antibiotic 
administration cannot be a control variable because 
antibiotics were given in different time frames after 
the rupture of membranes. These differences occur 
because Dr. Soetomo is a tertiary hospital so some 
patients came after being referred. It also depends 
on the time when patients decide to go to the hos-
pital after the rupture of membranes.
The collected data was analyzed by computeri-
zation with the Statistical Package for Social Scien-
ces (SPSS) software. Data is presented in the form 
of frequency distribution tables and described in 
narrative form. Analysis of the two variables that 
are thought to have a relationship is done through 
the Mann-Whitney and Fisher’s exact statistical tests 
that illustrate the comparison of influences between 
variables.
The Mann-Whitney test was conducted to deter-
mine whether there were differences in the effect 
of antibiotic therapy between groups used on the 
latency period. At first, a chi-square test was per-
formed to determine whether there are differences 
in infant outcomes between the types of antibiotics 
used. After the test is done, it was found that there 
were > 20% of tables that have an expected value 
of less than 5. Therefore, the p-value seen is the 
p-value of Fisher's exact test.
Results
Demographic Data
A total of 242 patients with history of PPROM were 
found in the medical records of Dr. Soetomo Sura-
baya General Hospital during the period of January 
– December 2017. Out of the total, there were only 
123 patients who gave birth in Dr. Soetomo Suraba-
ya General Hospital. Among them, there were only 
52 patients who met the inclusion criteria.
In general, pregnant women with a history of 
PPROM are mostly in the age group of 20-35 
years, which is as much as 61.5%. It is more com-
mon in multigravida women, with a percentage of 
48.3%. Most PPROM occurred in the 24-31 week 
gestational age group, which was 40.4% and the 
least frequency at gestational age <24 weeks as 
much as 3.8%. There were 54% of samples with 
an estimated birth weight (EBW) ≥ 1500 grams 
when PPROM occurs and 46% with EBW <1500 
grams. 
There were 76.9% of samples that gave birth 
through vaginal delivery and 23.1% through cesa-
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rean section. About 51.9% of the labor happens 
after being induced or terminated and 48.1% occur 
spontaneously. There were 36.7% of babies born 
with low birth weight (LBW), 28.6% with very low 
birth weight (VLBW), 22.4% with normal weight, 
and 12.2% with extremely low birth weight (ELBW). 
The majority of the 1st minute Apgar score was 
low (<7) with the percentage of 55.3%, but 59.6% 
of the 5th minute Apgar score was more than 7. 
Approximately 5.8% baby died within the first 24 
hours after labor. Also, we found that 100% of wo-
men with PPROM didn’t suffer any infection after 
the rupture of membranes. 
Table 1 shows the demographic data based on 
each antibiotic therapy used. Some of the data like 
the gestational age might be a moderator or inter-
vening variable, which is a variable that can affect 
the dependent variable in this study or the latency 
period.
Antibiotic use
It was found that there were no other antibiotics 
used for PPROM patients at Dr. Soetomo Surabaya 
General Hospital apart from cefotaxime or ceftria-
xone. There were only two regimens found to be 
used, which are cefotaxime given at a dose of 3 
grams once and ceftriaxone given at a dose of 2 
grams once dissolved in a 100cc intravenous NaCl 
0,9% (normal saline/PZ) infusion. 
The latency period consists of the time between 
the rupture of membranes (ROM) and antibiotic 
administration and the time from antibiotic admi-
nistration until labor. Instead of using mean, the 
median was used to represent data broadly in this 
study because of the non-normal distribution. Figu-
re 1 shows that the length between the ROM and 
antibiotic administration was shorter and the time 
until labor was longer in the cefotaxime group. It 
can be interpreted that antibiotic was administrated 
sooner in the cefotaxime group and the latency pe-
riod in the cefotaxime group involved more antibio-
tics than in the ceftriaxone group. 
Table 1. Demographic data.
Demographic Data
Cefotaxime Ceftriaxone
n = 45 (%) n = 7 (%)
Age
<20 years 15.6 0
20-35 years 57.8 85.7




<24 weeks 4.4 0
24-31 weeks 37.8 57.1
32-33 weeks 20 0
34-36 weeks 37.8 42.9
Estimated Birth Weight (EBW)
<1500 grams 41.9 71.4
≥1500 grams 58.1 28.6
Mode of Delivery
Pervaginam 73.3 100




≥2500 grams (Normal) 21.4 28.6
1500-2499 grams (LBW) 40.5 14.3
1000-1499 grams (VLBW) 28.6 28.6
<1000 grams (ELBW) 9.5 28.6










Death within 24 hours 6.7 0
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Figure 1:  Time Mapping between The Ruptures 
of Membranes (ROM), Antibiotic Admi-
nistration, and Labor
Figure 2: Percentage of Latency Period Length
Table 2. Latency period based on gestational age and Mann-Whitney test.
Gestational Age
Median of Latency Period (hours)
P valueCefotaxime Ceftriaxone 
Weeks Median Min Max Med Min Max 
<24 35,92 17,83 54 there are no samples in 
0.601
24-31 74,17 7,3 200,5 127,48 34,17 193,18 
32-33 64,08 19,75 320,5 there are no samples in 
34-36 33,67 8,28 85,58 26,45 24,78 29,37 
Total 52,67 7,3 320,5 34,17 24,78 193,18 
Table 3. Infant outcomes.
Infant Outcomes
Cefotaxime Ceftriaxone
P valueN % N %
Mean Notes Mean Notes
Birth Weight (grams) 1821,43 LBW 1471,43 VLBW 0.339
APGAR Score 1st minutes 5 Moderately depressed 5 Moderately depressed 0.711
APGAR Score 5th minutes 6 Moderately depressed 6 Moderately depressed 0.131
It was found that there were 57,8% of cefota-
xime group samples which have latency period of 
>48 hours, whereas in ceftriaxone there were only 
42,9% (Figure 2)
Analysis Results
The Mann-Whitney test shown a P-value of 0.601 
(p >0.05), which means that there were no statisti-
cal differences. The duration of the latency period 
was illustrated through the median because of the 
non-normal distribution. If seen as a whole regard-
less of a certain gestational age group, the median 
latency period of cefotaxime group is 52 hours and 
40 minutes and ceftriaxone group is 34 hours and 
10 minutes. In Table 2 & 3 there are no differences in all 
aspect of infant outcomes between the two antibiotics.
Discussion
The most frequently used antibiotic is cefotaxime 3 
grams once given until labor. This therapeutic choi-
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ce does not match the recommendations of Indo-
nesian Association for Obstetrics and Gynaecology 
(POGI) (2016) and WHO (2015), which states that 
erythromycin is the first choice for prophylaxis after 
PPROM. The difference in this use of antibiotics can 
be due to the administration of antibiotics adjus-
ted to their susceptibility to the bacteria that cause 
infection. In the previous research, cephalosporin 
as first-line therapy for the care of mothers and 
newborns in PPROM is indicated because of the 
high susceptibility of Escherichia coli to antibiotics 
[12]. Escherichia coli was one of the most common 
microorganism isolated from women with PPROM 
along with Staphylococcus or Streptococcus spe-
cies [14-16]. In addition, the most common bacteria 
which cause urinary tract infection (UTI) is Escheri-
chia coli, where UTI is one of the causes of preterm 
labor in PPROM [17, 18]. 
The cephalosporins are divided into 3 generations 
according to their spectrum of activity, where ac-
tivity against gram-negative bacilli increases from 
first- to third-generation drugs [19, 20]. Third-ge-
neration cephalosporins are preferred in many cli-
nical situations because of their proven record of 
clinical efficacy, favorable pharmacokinetics and low 
frequency of adverse effect [21]. Cefotaxime, cef-
triaxone and other cephalosporins are safe to be 
used during pregnancy and considered as category 
B by FDA [22]. Cefotaxime was found to have the 
best gram-positive coverage of the 3rd generation 
agents, but ceftriaxone was as safe and as effective 
as cefotaxime in treating serious bacterial infections 
[21, 23-25]. A study conducted in Malang, East Java, 
Indonesia showed that cefotaxime generally was 
more cost-effective than ceftriaxone which made 
cefotaxime more preferable [26].
It was found that cefotaxime group was able to 
extend the latent period longer, with a median of 
approximately 2 days and maximum 13 days. As 
seen in Figure 1, antibiotic in the cefotaxime group 
was used more effectively since the sooner admi-
nistration of antibiotic after ROM occurred was as-
sociated with a better outcome [7]. Also, as seen 
in Figure 2, the median and the majority of latency 
period in the cefotaxime group was more than 48 
hours, where 48 is the time required until the corti-
costeroid given has worked to stimulate pulmonary 
maturation [27]. This result can be caused by the 
majority of pregnant women treated with cefotaxi-
me being in the 24-31 week gestational age group 
whereas those treated with ceftriaxone didn’t have 
any sample in that age group as shown in Table 1 
and 2. According to Melamed et al. [8], the duration 
of the latency period ranges between 0 and 59 
days and is inversely proportional to the gestational 
age at admission. Women with a short latent pe-
riod (<48 hours) are characterized by a higher rate 
of cervical dilatation and a higher gestational age 
at entry and are more likely to be nulliparous [8]. 
However, no other studies are comparing these 2 
antibiotic regimens.
A study that also compared the latency period 
between antibiotics from the cephalosporin group 
by Fortunato et al. [28], stated that there was no 
difference in the latency period between patients 
treated with ceftizoxime and those given other anti-
biotic therapy (cefoxitin, cefazolin, ampicillin). Other 
studies by Lee et al. [29], stated that a new combi-
nation of antibiotics consisting of ceftriaxone, cla-
rithromycin, and metronidazole was able to extend 
the latency period longer with a median value of 
23 days, compared to the therapeutic regimen of 
ampicillin and/or cephalosporin alone which had a 
median value of 12 days. 
Another comparison to be considered is the 
worldwide recommended erythromycin which is still 
recommended because there have been many stu-
dies on its effectiveness for PPROM [30]. According 
to WHO (2015), the choice of erythromycin was 
based on the findings of ORACLE I study with over 
2000 women, which showed that erythromycin de-
creases the risk of necrotizing enterocolitis (NEC) in 
the newborn compared to co-amoxiclav [7]. Another 
study that supports the use of erythromycin sta-
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ted that erythromycin was found to be associated 
with a decrease in the primary composite outcome 
(neonatal death, chronic lung disease or major ce-
rebral abnormality on ultrasound; p = 0.08) and in 
single adverse neonatal outcomes (p = 0.02) when 
compared to placebo [31]. However, a recent study 
mentioned that erythromycin alone is insufficient 
to control the growth of Gram-positive and Gram-
negative bacteria in patients with PPROM [15]. In 
particular, Escherichia coli and group B Strepto-
coccus isolates showed high rates of resistance to 
erythromycin [15, 32].
Seelbach-Goebel [33], summarized the results of 
the ORACLE I trials which state that 60.9% of preg-
nant women given erythromycin 4x/day orally give 
birth within 7 days after the rupture of membranes. 
There were no differences in latency to delivery, 
incidence of chorioamnionitis, or neonatal outco-
mes when erythromycin was compared with other 
drugs from one class of macrolides, azithromycin 
[34, 35]. The latency period after erythromycin ad-
ministration was 65,6 hours and azithromycin 61,7 
hours [36].
Other regimens, amoxicillin/clavulanic acid 325 mg 
4 ×/day orally or erythromycin 250 mg + amoxicillin/
clavulanic acid 325 mg, which all mentioned in ORA-
CLE I trial were also associated with a significantly 
lower rate of deliveries within 48 hours compared 
to placebo [33]. But a fourfold higher rate of NEC 
was found in both groups treated with amoxicillin/
clavulanic acid [33]. 
Several protocols recommend other different 
choices of antibiotic. Some Latin American coun-
tries recommend the use of ampicillin or amoxici-
llin [12]. Those antibiotics also showed a significant 
increase in the latency period and a lower inciden-
ce of clinical amnionitis [12, 37]. But the use of 
ampicillin and amoxicillin was related to adverse 
symptoms, such as nausea, vomiting and abdomi-
nal pain [37, 38]. Thus, amoxicillin and ampicillin 
are often replaced by a cephalosporin in clinical 
practice [38].
Based on the infant outcomes, both antibiotic 
groups have the same low birth weight output, 
even though cefotaxime group has a slightly hig-
her value. In the Fisher’s exact test, p-value in lower 
case = 0.339 was obtained, which means there was 
no difference in birth weight of babies between 
antibiotic therapy A and B. In accordance with the 
ORACLE Trial I study conducted between 1994 and 
2000, the use of antibiotics was not directly related 
to birth weight [30, 33]. But a randomized contro-
lled trial using oral ampicillin 1 g (n = 59) vs pla-
cebo (n = 51), showed that the mean birth weight 
was significantly higher in those received ampicillin 
(2885 vs. 2336 g; P < 0.05) [39].
The Apgar score provides an accepted and con-
venient method for reporting the status of the 
newborn infant immediately after birth and the res-
ponse to resuscitation if needed [40]. The average 
Apgar score both in the first minute and the fifth 
minute were identical between the two groups. In 
line with the Fisher’s exact test which showed that 
there were no differences in the Apgar score bet-
ween the two types of antibiotics used. The Apgar 
score is influenced by the length of the latency pe-
riod. Salan [41], found that there was a correlation 
between the length of the latency period and the 
infant Apgar results with P <0.001 and the Odds 
ratio was 8.5, which means that the length of the 
latent period affected the infant Apgar score with 
an 8.5-fold increased risk.
Conclusion 
Based on this study, the most commonly used the-
rapeutic regimen is cefotaxime 3 grams once given 
until labor. No differences were found in latency 
period and infant outcomes in terms of birth weight 
and Apgar scores between the use of cefotaxime 
and ceftriaxone. But cefotaxime appears to be more 
able to extend the latency period for more than 48 
hours which gives better prospects for fetal lung 
maturation and more cost-effective than ceftriaxo-
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ne. There was no incidence of infection after the 
rupture of membranes with the use of these two 
antibiotics, which mean that cephalosporin has 
succeeded in preventing infections in women with 
PPROM. This research, however, is subject to seve-
ral limitations since the sample of the ceftriaxone 
group was small.
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